211 related articles for article (PubMed ID: 7959255)
1. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies.
Cohen I; Tepper R; Rosen DJ; Shapira J; Cordoba M; Dror Y; Altaras M; Beyth Y
Gynecol Oncol; 1994 Oct; 55(1):138-43. PubMed ID: 7959255
[TBL] [Abstract][Full Text] [Related]
2. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
[TBL] [Abstract][Full Text] [Related]
4. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
5. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
6. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients.
Cohen I; Rosen DJ; Shapira J; Cordoba M; Gilboa S; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1994 Feb; 52(2):185-90. PubMed ID: 8314137
[TBL] [Abstract][Full Text] [Related]
7. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.
Kavak ZN; Binöz S; Ceyhan N; Pekin S
Acta Obstet Gynecol Scand; 2000 Jul; 79(7):604-7. PubMed ID: 10929963
[TBL] [Abstract][Full Text] [Related]
8. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I
Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946
[TBL] [Abstract][Full Text] [Related]
9. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Altaras MM; Shapira J; Tepper R; Cordoba M; Figer A; Zalel Y; Dror Y; Beyth Y
Gynecol Obstet Invest; 1997; 43(1):60-3. PubMed ID: 9015703
[TBL] [Abstract][Full Text] [Related]
10. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow.
Develioğlu OH; Omak M; Bilgin T; Esmer A; Tüfekçi M
Gynecol Oncol; 2004 May; 93(2):328-35. PubMed ID: 15099941
[TBL] [Abstract][Full Text] [Related]
11. Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen.
Lubian López DM; Fernandez YG; Rodríguez BR; López FM; Delgado RC
Menopause; 2010; 17(3):487-93. PubMed ID: 20464783
[TBL] [Abstract][Full Text] [Related]
12. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
13. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.
Mourits MJ; Van der Zee AG; Willemse PH; Ten Hoor KA; Hollema H; De Vries EG
Gynecol Oncol; 1999 Apr; 73(1):21-6. PubMed ID: 10094875
[TBL] [Abstract][Full Text] [Related]
14. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen.
Gao WL; Zhang LP; Feng LM
Chin Med J (Engl); 2011 Aug; 124(15):2335-9. PubMed ID: 21933565
[TBL] [Abstract][Full Text] [Related]
16. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen.
Lindahl B; Andolf E; Ingvar C; Liedman R; Ranstam J; Willén R
Anticancer Res; 1997; 17(5B):3821-4. PubMed ID: 9427787
[TBL] [Abstract][Full Text] [Related]
17. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
18. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen.
Bertelli G; Valenzano M; Costantini S; Rissone R; Angiolini C; Signorini A; Gustavino C
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):275-7. PubMed ID: 10985880
[TBL] [Abstract][Full Text] [Related]
19. Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women.
Cohen I; Azaria R; Shapira J; Yigael D; Tepper R
Cancer; 2002 Jun; 94(12):3101-6. PubMed ID: 12115340
[TBL] [Abstract][Full Text] [Related]
20. [Some specifics of tamoxifen's effect on the endometrium in menopausal cancer patients].
Ashtrafian LA; Antonova IB; Chazova NL; Motskobili TA; Babaeva NA; Al'ditskiĭ IA
Vopr Onkol; 2005; 51(2):200-5. PubMed ID: 16223001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
